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Abstract
Background: Patients with HER2-overexpressing metastatic breast cancer, despite initially benefiting from the
monoclonal antibody trastuzumab and the EGFR/HER2 tyrosine kinase inhibitor lapatinib, will eventually have
progressive disease. HER2-based vaccines induce polyclonal antibody responses against HER2 that demonstrate
enhanced anti-tumor activity when combined with lapatinib in murine models. We wished to test the clinical
safety, immunogenicity, and activity of a HER2-based cancer vaccine, when combined with lapatinib.
Methods: We immunized women (n = 12) with metastatic, trastuzumab-refractory, HER2-overexpressing breast
cancer with dHER2, a recombinant protein consisting of extracellular domain (ECD) and a portion of the
intracellular domain (ICD) of HER2 combined with the adjuvant AS15, containing MPL, QS21, CpG and liposome.
Lapatinib (1250 mg/day) was administered concurrently. Peripheral blood antibody and T cell responses were
measured.
Results: This regimen was well tolerated, with no cardiotoxicity. Anti-HER2-specific antibody was induced in all
patients whereas HER2-specific T cells were detected in one patient. Preliminary analyses of patient serum
demonstrated downstream signaling inhibition in HER2 expressing tumor cells. The median time to progression
was 55 days, with the majority of patients progressing prior to induction of peak anti-HER2 immune responses;
however, 300-day overall survival was 92% (95% CI: 77-100%).
Conclusions: dHER2 combined with lapatinib was safe and immunogenic with promising long term survival in
those with HER2-overexpressing breast cancers refractory to trastuzumab. Further studies to define the anticancer
activity of the antibodies induced by HER2 vaccines along with lapatinib are underway.
Trial registry: ClinicalTrials.gov NCT00952692
Keywords: HER2, Antitumor immunity, Immunization, Breast cancer
Introduction
The human epidermal growth factor receptor 2 (HER2),
overexpressed in 20-30% of breast cancers, is associated
with more aggressive tumor behavior [1]. Treatment
with combinations of the anti-HER2 antibody trastuzu-
mab and chemotherapy lengthens survival in patients
with metastatic HER2-overexpressing breast cancer [2].
However, progressive disease typically occurs within one
year. Lapatinib, a potent reversible inhibitor of HER2
and epidermal growth factor receptor (EGFR) tyrosine
kinases [3], in conjunction with chemotherapy, increases
time to progression in these patients [4]. Unfortunately,
responses to lapatinib are generally short-lived, and pro-
gression remains a significant clinical problem.
Intriguingly, the overexpression of HER2 persists in
trastuzumab and lapatinib-refractory tumors [5,6], and
thus, targeting HER2 with cancer immunotherapy is a
potentially effective strategy. A variety of vaccines tar-
geting HER2, based on proteins, peptides, modified
tumor cells, viral vectors, pDNA and dendritic cells
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studies of HER2-targeting cancer vaccines [7] have
demonstrated that HER2 is immunogenic, and that
immune responses against HER2 may be associated with
an improved clinical outcome [8-13].
One protein-based vaccine, dHER2 Antigen-Specific
Cancer Immunotherapeutic (ASCI) a recombinant
HER2 protein, including a truncated intracellular
domain (ICD) and the complete extracellular domain
(ECD), combined with the immunological adjuvant
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evaluated in two early phase clinical studies of patients
with HER2-overexpressing breast cancer (NCT
00058526 and NCT 00140738) [14]. In both studies, the
data showed that dHER2 immunizations were well toler-
ated, consistently immunogenic at the 500 μgd o s ea n d
that clinical activity (including prolonged stable disease)
was associated with antibody and T cell responses.
One important observation from the prior dHER2
ASCI studies was that the polyclonal antibody-contain-
ing serum from immunized patients had functional
activity against signaling pathways mediated by HER2.
Specifically, incubation of breast cancer cell lines with
s e r u mf r o mt w oi m m u n i z e dp a t i e n t sd e m o n s t r a t e da n
impact on molecular pathways resembling that of trastu-
zumab [14]. Because clinical trials have demonstrated
that combinations of lapatinib and trastuzumab lead to
enhanced clinical activity and combined effects on sig-
naling pathways [15], there has been interest in combin-
ing the polyclonal anti-HER2 serum with trastuzumab
and indeed, increased apoptosis of human HER2-overex-
pressing breast cancer cells was observed when lapatinib
was combined with HER2-specific polyclonal antisera
generated from rabbits immunized with dHER2 ASCI
[16]. We therefore hypothesized that the lapatinib would
enhance the anti-signaling activity of the polyclonal Abs
induced by the dHER2 vaccine in humans. First, it was
necessary to establish that the induction of anti-HER2
antibodies by the dHER2 vaccine was not affected by
lapatinib and this was the primary purpose of this study.
Methods
Patients
Patients provided consent under a protocol approved by
the Duke University Medical Center Institutional Review
Board. Enrollment requirements were age 18 or older,
stage IV HER2- overexpressing (HER2 3+ or FISH +)
breast cancer, documented disease progression or
relapse following at least one prior standard therapy
containing trastuzumab, ECOG status of 0 or 1, ade-
quate hematologic counts, hepatic and renal function
and an LVEF of 50% or greater. Concurrent bisphospho-
nates and hormonal therapy were permitted. Prior che-
motherapy and/or trastuzumab were required to have
been discontinued no sooner than four and three weeks,
respectively, before the first ASCI administration. Initi-
a l l y ,p r i o rl a p a t i n i bw a sn o tp e r m i t t e d ;h o w e v e r ,t h i s
severely limited enrollment and therefore, an amend-
ment was made to permit prior and ongoing lapatinib
use. Known autoimmune disease, immunosuppressive
therapies or HIV, significant cardiovascular disease or
arrhythmias were exclusionary criteria.
Treatment/Monitoring
The dHER2 ASCI containing 500 μg of recombinant
dHER2 protein (a truncated intra-cellular sequence
(ICD) and the complete extracellular sequence (ECD)),
reconstituted in the AS15 adjuvant, a liposomal formu-
lation containing MPL, QS21 and CpG, was adminis-
tered intramuscularly every 2 weeks for 6
administrations (See Figure 1 depicting one cycle). Up
to three total cycles of immunization were permitted
unless discontinued due to progression of disease. Clini-
cal tumor evaluations were conducted at baseline and at
the end of the cycles (e.g., week 12, week 26). Lapatinib
(1250 mg) was taken by mouth daily.
Cardiac monitoring consisted of a 12-lead ECG at
screening, and at week 12, week 26, and follow-up visit
#1 and a MUGA evaluation of ejection fraction (EF) at
screening, week 6, 12, 20, 26, follow-up visits #1 and #4.
Analysis of anti-HER2 antibody binding by ELISA
Serum was collected pre- (week 0) and every 2 weeks
while on study. 96-well plates were coated with HER2
ICD protein (5 μg/well) or HER2 ECD protein (5 μg/
well) and incubated with 100 μl of serially diluted
patient serum or trastuzumab. Plates were then incu-
bated with mouse anti-human IgG conjugated alkaline
phosphatase (AP) (Sigma) and developed using p-nitro-
phenyl phosphate (Sigma). Absorbance (415 nm) was
read using a BioRad microplate reader. Titers were
defined as the greatest dilution at which the mean
absorbance was at least twice negative control.
ELISPOT analysis
IFN-g ELISPOT assays (Mabtech Inc., Cincinnati, OH)
were performed according to the manufacturer’s instruc-
tions as previously described 16]. Briefly, PBMC
(250,000 cells/well) were added to each well and stimu-
lated overnight with HER2 ICD or HER2 ECD overlap-
ping peptide mixes (1 μg/ml) to detect HER2-specific
responses, or CMV peptide mix (2.6 μg/ml), HIV pep-
tide mix (2.6 μg/ml) (both from BD Bioscience) and a
mixture of PMA (50 ng/ml) and Ionomycin (1 μg/ml) as
controls. Results were normalized to the number of
spots per 1 × 10
6 PBMC. Based on our previously
reported experience [17], a positive response was
defined as an increase by ≥ 40 spots from baseline.
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Descriptive statistics are presented. Progression-free
interval was defined as time from trial enrollment to
disease progression or death, whichever came first.
Overall survival was defined from time of enrollment
until death due to any cause. Progression-free and over-
all survival was calculated using the Kaplan-Meier pro-
duct limit method.
Results
Patient demographics
Twelve (12) patients were enrolled and received treat-
ment on trial. Demographics are listed for each patient
in Table 1. Of note, the patients had substantial meta-
static disease burden and had been heavily pretreated,
all having progressed on prior trastuzumab and 10/12
having progressed on a lapatinib-containing regimen.
Four patients completed one full cycle and one com-
pleted two full cycles of immunization.
dHER2 ASCI vaccination in combination with lapatinib
was well tolerated. The most common adverse events (AE)
encountered were “constitutional symptoms” such as mus-
culoskeletal pain (8/12, 66% with 0% grade 3), injection
site reactions (6/12, 50% with 0% grade 3), myalgia (5/12,
42% with 0% grade 3) and fatigue (5/12, 42% with 1/12,
9% grade 3 due to progression of disease). There were
only two serious adverse events (SAE) on study: one
patient experienced chest pain which was determined to
be secondary to progression with mediastinal lymphade-
nopathy and one patient suffered a pulmonary embolism
deemed not related to treatment. There was one additional
grade 3 AE: epistaxis after a lacrimal duct repair. There
were no grade 4 AEs observed.
Cardiac function was closely monitored during this
study with two evaluations of left ventricular ejection
fraction (LVEF) at the beginning of every cycle. No
heart failure or any decrease in left ventricular cardiac
ejection fraction ≥ 20% relative to baseline was seen for
any patient at any time point on trial.
Antigen specific T Cell and antibody responses
We analyzed HER2 ICD and ECD specific antibody
responses by ELISA. All patients had a detectable anti-
ICD-antibody response (ranging from 1:200 to 1:6400)
following vaccination in the context of lapatinib treat-
ment. We observed an increase in HER2 ICD antibody
titer starting as early as week 4 (after 2 injections; 9 of
12 patients) (Figure 2).
Figure 1. 
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Figure 1 Study treatment schematic.
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ECD-specific antibodies was complicated by detection of
pre-vaccination HER2-ECD specific antibodies (due to
residual trastuzumab) in the sera of 9 of the 12 patients
who had been receiving trastuzumab 23 to 60 days prior
to study entry (Figure 3). The 3 patients who did not
receive trastuzumab within 2 months of starting the
study (patients 4, 5, 12) did not exhibit pre-existing anti-
bodies to HER2-ECD, but had detectable post vaccina-
tion HER2-ECD specific responses ranging from 1:100
to 1:1600 (Figure 3). For these 3 patients, the dynamics
of the HER2-ICD and -ECD antibody responses over
time indicate that HER2-specific antibodies were detect-
able between 4 to 6 weeks after initiating the vaccina-
tions (i.e., following 3-4 vaccinations) with a greater
antibody titer specific for HER2-ICD compared to
HER2-ECD (Figures 2 and 3). An additional two
patients with detectable pre-vaccination anti-ECD anti-
bodies demonstrated an increase in HER2-ECD antibody
titer following vaccination (Figure 3). In the remainder
of patients, the pre-vaccination HER2 ECD titers levels
were not increased after vaccination, making an accurate
assessment of the vaccine induced HER2 ECD-specific
response difficult.
HER2 specific T cell responses were analyzed by IFNg
ELISPOT assay on cryopreserved, non-restimulated per-
ipheral blood specimens obtained at each timepoint.
There were increments in the ECD-specific T cell pre-
cursor frequency in one patient and in the ICD-specific
T cell precursor frequency in four patients; however,
using a pre-specified definition of a positive response as
an increase in 40 spots over pre-vaccination frequency,
there was a single patient with an ECD-specific T cell
response and none with an ICD-specific T cell response
(Additional file 1: Table S1). This patient appears to
have had a pre-existing ECD-specific response which
was boosted with the vaccine.
Clinical outcome
There were no objective clinical responses. One patient
remained progression free on trial for 6 months. Median
time to progression was 55 days (range: 41-188) (Figure
4a). Ten of 12 patients remain alive in follow-up. Over-
all survival at 300 days was 92% (95% CI: 77-100%) (Fig-
ure 4b). Because of the small numbers of patients, we
could not statistically compare TTP or overall survival
with immune responses; however, there were no obvious
correlations.
Discussion
The purpose of this study was to determine the clinical
and immunologic effects of immunization against HER2
concurrent administration of the HER2 tyrosine kinase
inhibitor lapatinib. Previously, we reported that a HER2-
targeting vaccine could induce antibody and T cell
responses when administered concomitantly with lapati-
nib in a murine model [18]. We extended this work in
the present study confirming for the first time in
humans that concomitant administration of lapatinib
did not appear to affect the immune response induced
by the HER2 immunotherapy. Although we are not
aware of other data regarding the effect of lapatinib on
the immune response in humans, other tyrosine kinase
inhibitors have demonstrated negative effects on the
immune response, such as sorafenib (which targets RAF
protein in the EGFR pathway as well as other targets)
Table 1 Patient characteristics
Pt # Age Race ER or PR
+
# prior lines
tx
# met
sites
Trastuzumab in prior regimen (days
since)
Prior
Lapatinib
#
injections
PFS
(d)
OS
(d)
001 45 W Y 4 2 Y (23) N 4 53 615+
002 50 W Y 3 3 Y (34) P 6 82 484
003 48 W N 3 4 Y (24) C 6 85 596+
004 53 W N 6 1 N C 6 86 549+
005 63 W Y 2 2 N C 4 48 540+
006 60 W N 5 4 Y (37) C 6 86 531+
007 46 B N 4 1 Y (33) P 5 69 486+
008 65 W N 8 3 Y (27) C 3 41 456+
012 55 W N 3 2 N C 5 69 216
013 65 W N 4 2 Y (27) C 4 55 316+
014 56 W N 3 2 Y (25) C 12 188 310+
015 46 B Y 3 4 Y (21) N 4 69 274+
Median 54 3.5 2 5 69
1) Prior Lapatinib Use (N = no prior use, P = previous progression on lapatinib, but not on regimen immediately prior, C = continued use, patient was on
lapatinib in immediately prior regimen and continued the medication onto trial). 2) OS (overall survival): “+” indicates that the patient was still alive at the last
follow-up date
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effects or potentially improve immune responses [19,20].
We observed potent antibody responses to HER2 ECD
and ICD, suggesting that we could still break tolerance
to a self-antigen in the context of lapatinib. In the prior
phase I/II studies of dHER2 ASCI, antibody responses
were consistently observed, and CD4+ and CD8+ T cell
responses were also reported. The preferential induction
of antibodies using HER2 protein-based vaccines has
been already reported. In a series of patients immunized
with the truncated 146HER2 protein complexed with
cholesteryl pullulan alone or with various adjuvants
[21-23], antibody responses against HER2 were detected
in 14 of 15 patients, but only 5 out of 9 developed
detectable HER2-specific CD8+ and/or CD4+ T-cell
immune responses. Because the development of antibo-
dies generally requires Th2 cells, but our method for
measuring IFN-gamma ELISPOT identifies Tc1 and
Th1, and not Th2 responses, it is possible that a Th2
response occurred, but was not detectable. It is also pos-
sible, as has been reported by others using protein-based
vaccines, that regulatory T cells (Treg), typically
increased in advanced cancer patients, caused decreases
in T cell responses [24]. Future strategies to induce
greater T cell responses could be warranted as some
authors have suggested the T cell responses correlate
with clinical outcome [25]. We have developed a series
of recombinant viral vectors expressing HER2 that have
been evaluated preclinically and were shown to induce
HER2-specific CD8+ T cells. These vectors will be
entering clinical trials shortly [26]. We have also
reported strategies for depleting Treg [27].
One emerging aspect of cancer immunotherapy is that
long periods (between 4 to 6 immunizations) are needed
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Figure 2. HER2 ICD ELISA
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Figure 2 HER2-ICD specific antibody response. Serum from patients receiving dHER2-ASCI + lapatinib was analyzed for HER2-ICD specific
antibodies by ELISA. Plates were coated with HER2-ICD protein and incubated with serial dilutions of patient sera (1:25-1:6400), along with
negative control serum. Individual graphs of the HER2-ICD titer over time are presented for each patient (indicated by study number) with
arrows indicating final dHER2ASCI injection.
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noted that some patients rapidly progressed during
immunization, but prior to development of detectable
HER2 specific antibody responses, or until the antibody
responses are of sufficient quantity or quality to impact
disease. In most cases these were patients who had been
maintained on trastuzumab prior to participation. The
decline in anti-ECD Ab responses in the early weeks of
the study likely represents trastuzumab levels declining.
This suggests that for future vaccine studies, patients
may need to receive concomitant trastuzumab until they
have an adequate induction of antibody responses. Disis
et al.s h o w e dt h a tp a t i e n t sc o u ld be vaccinated in the
setting of trastuzumab without additional toxicity. The
expected immune responses including epitope and anti-
gen spreading were observed [28]. Indeed, in our study,
two patients with detectable pre-vaccination anti-ECD
antibodies demonstrated an increase in HER2-ECD anti-
body titer following vaccination (Figure 3), suggesting
we could also induce antibody responses against the
dHER2 despite the presence of trastuzumab.
Recent clinical trials have established longer survival
for patients receiving trastuzumab plus lapatinib, sug-
gesting clinical benefit for antibody plus tyrosine kinase
inhibition of HER2. Because this was not a randomized
trial, we are not able to determine the clinical benefit of
combined dHER2 ASCI plus lapatinib; however, our
observed median PFS and overall survival in a heavily
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Figure 3.  HER2 ECD ELISA
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Figure 3 HER2-ECD specific antibody response. Serum from patients receiving dHER2-ASCI + lapatinib was analyzed for HER2-ECD specific
antibodies by ELISA. Plates were coated with HER2-ECD protein and incubated with serial dilutions of patient sera (1:25- 1:6400), along with
negative control serum and Herceptin as a positive control. Individual graphs of the HER2-ECD titer over time is represented for each patient
(indicated by study number) with arrows indicating final dHER2ASCI injection. Although all patients had received trastuzumab at some point in
the past, nine patients had received trastuzumab with their immediately prior systemic treatment regimen (range 21 to 37 days), while three had
received the trastuzumab during a more distant systemic treatment reginmen. The numbers of days between receiving trastuzumab and starting
study drug is noted on each graph as applicable. A * indicates samples taken once trastuzumab was restarted by the patient
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who had progressive disease on trastuzumab and prior
lapatinib compares favorably with other clinical data.
For example, although there is insufficient data in the
literature regarding the outcome of patients refractory
to both drugs, among patients who have progressive dis-
ease while receiving trastuzumab therapy, overall survi-
val has ranged from 10 - 19 months [29-31]. In the
EGF104900 study, which randomized patients who had
progressed on trastuzumab to either lapatinib alone or
lapatinib in combination with trastuzumab, PFS of 8
weeks and OS of 39 weeks (or 273 days) was reported
for the lapatinib only arm [31]. It has also been observed
in some immunotherapy studies, that OS is improved
despite a lack of effect on PFS suggesting that delayed
effects of the vaccine might have led us to prematurely
discontinue immunization. Future studies should permit
a greater extent of progression (such as 50% growth) in
asymptomatic progression as has been suggested in the
literature [32].
Another important aspect of the strategy of combining
a HER2 immunotherapy with lapatinib is the potential
combined inhibition of HER2 signaling. A detailed
analysis of effects of anti-HER2 serum by our group is
reported elsewhere (Rong et al., manuscript submitted).
For the current manuscript, we performed a preliminary
analysis in which antibodies, purified from post-vaccina-
t i o ns e r u mf r o ms e l e c t e dp a t i e n t s( P 0 0 2 ,P 0 0 4 ,a n d
P008), were tested for their ability to reduce phosphory-
lation of the downstream molecule AKT in the HER2
overexpressing cell line SKBR3. In the patient with the
highest titer of ECD among the three (P004), pAKT was
decreased by antibodies purified from the post-vaccina-
tion serum, providing a suggestion that there are anti-
signaling effects of the dHER2-induced antibodies
(Additional file 2: Figure S1). Serum from patients in
the previous phase I/II studies of dHER2 alone bound
HER2-overexpressing breast cancer cell lines and inhib-
ited growth of these cell lines with an effect on molecu-
lar pathways resembling that of trastuzumab [14]. We
previously reported that the polyclonal sera induced in
mice by a HER2 vaccine were superior to monoclonal
antibodies in mediating receptor internalization and
degradation, resulting in ablation of HER2 signaling
over time. Furthermore, there was increased anti-tumor
activity when this vaccine was administered concomi-
tantly with lapatinib to mice [18]. These data suggest a
potential advantage to our approach. First, the vaccine
may provide durable periods of exposure to biologic
levels of anti-HER2 antibody, whereas trastuzumab must
continue to be administered. Second, the vaccine
induces polyclonal antibody responses which could have
immunologic functions (such as antibody dependent cel-
lular cytotoxicity) as well as direct functions on HER2
signaling. Recently, it was reported that lapatinib
induced HER2 surface expression in HER2-positive
breast cancer cell lines, leading to the enhancement of
trastuzumab-mediated ADCC [33]. These potential
advantages strongly support the further assessment of
HER2-targeting immunotherapies with concomitant
lapatinib and/or trastuzumab in human clinical trials.
One potential disadvantage of the vaccine strategy is
that the antibody titers are lower than those achieved
during trastuzumab administration, suggesting future
vaccine strategies may need to enhance the titer of anti-
body induced. Based on the tolerability and safety estab-
lished in the current study, we will be embarking on a
s t u d yt oe v a l u a t et h eu s eo fv i r a lv e c t o r - b a s e dv a c c i n e
encoding HER2 along with lapatinib. The potential bene-
fits of such immunotherapeutic strategies over a mono-
clonal antibody approach (e.g., induction of both T cell
and polyclonal antibody responses with multiple mechan-
isms of action) warrant this testing. More broadly, we
believe that targeting receptor molecules using immu-
notherapy as a mean to perturb signaling offers potential
new opportunities to target cancer beyond the conven-
tional lytic killing of tumors by the immune system.
Figure 4 Outcomes for patients treated with dHER2 ASCI
vaccination and lapatinib. a) Kaplan Meier Plot Progression Free
Survival b) Overall Survival.
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Page 7 of 9In summary, the data presented is consistent with
prior preclinical and clinical observations and supports
the expansion of combination studies. However, the lim-
ited numbers of patients, the inability to assess clinical
responses compared with controls, and the potential
effects of waning trastuzumab levels are challenges that
would be best addressed in a randomized trial.
Additional material
Additional file 1: Table S1. dHER2ASCI ELISpot results: Number of IFNg
producing.
Additional file 2: Figure S1. Reduced phosphorylation of AKT following
dHER ASCI immunization.
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